Alvotech higher on positive data backing biosimilar to Takeda's Entyvio
Source: SeekingAlpha
2026-02-05 08:15:45 ET
More on Alvotech, Takeda Pharmaceutical
- Takeda Tests New Highs, But Struggles To Find Entyvio Successor
- Takeda Pharmaceutical Company Limited (TAK) Q3 FY2025 Earnings Call Transcript
- Alvotech: Why FDA Delays Don't Break The Bull Case
- Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
- Takeda Pharmaceutical Non-GAAP EPS of ¥428.00, revenue of ¥3411.2B; updates FY26 outlook
Read the full article on Seeking Alpha
For further details see:
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio
Alvotech
NASDAQ: ALVO
ALVO Trading
1.64% G/L:
$4.025 Last:
241,961 Volume:
$4.16 Open:
ALVO Latest News
February 05, 2026 03:00:00 am
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
February 02, 2026 03:00:00 am
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
January 29, 2026 03:00:00 am
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
